Compare Stocks: NBP, RIGL, FTH, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$34.71 +8.5%	$27.27	$7.45 ▼ $37.90	$896.91M	-0.25	212,135 shs	448,465 shs
NBP I-Mab	$1.89 -5.5%	$1.78	$1.46 ▼ $6.79	$218.58M	1.47	747,108 shs	271,588 shs
PHAR Pharming Group	$11.46 -3.3%	$12.59	$9.62 ▼ $21.34	$811.14M	-0.01	19,227 shs	23,168 shs
RIGL Rigel Pharmaceuticals	$45.11 -1.7%	$39.39	$24.95 ▼ $52.24	$834.63M	1.16	376,326 shs	541,979 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	0.00%	-1.05%	+13.11%	+3,199,999,900.00%	+3,199,999,900.00%
NBP I-Mab	0.00%	+2.04%	+12.99%	+12.99%	+199,999,900.00%
PHAR Pharming Group	0.00%	+1.11%	-5.99%	-5.95%	-13.50%
RIGL Rigel Pharmaceuticals	0.00%	+7.77%	+24.90%	+58.19%	+10.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$34.71 +8.5%	$27.27	$7.45 ▼ $37.90	$896.91M	-0.25	212,135 shs	448,465 shs
NBP I-Mab	$1.89 -5.5%	$1.78	$1.46 ▼ $6.79	$218.58M	1.47	747,108 shs	271,588 shs
PHAR Pharming Group	$11.46 -3.3%	$12.59	$9.62 ▼ $21.34	$811.14M	-0.01	19,227 shs	23,168 shs
RIGL Rigel Pharmaceuticals	$45.11 -1.7%	$39.39	$24.95 ▼ $52.24	$834.63M	1.16	376,326 shs	541,979 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	0.00%	-1.05%	+13.11%	+3,199,999,900.00%	+3,199,999,900.00%
NBP I-Mab	0.00%	+2.04%	+12.99%	+12.99%	+199,999,900.00%
PHAR Pharming Group	0.00%	+1.11%	-5.99%	-5.95%	-13.50%
RIGL Rigel Pharmaceuticals	0.00%	+7.77%	+24.90%	+58.19%	+10.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTH Sensei Biotherapeutics	2.85	Moderate Buy	$55.00	58.46% Upside
NBP I-Mab	2.00	Hold	$9.00	376.19% Upside
PHAR Pharming Group	2.20	Hold	$38.67	237.41% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	30.79% Upside

Current Analyst Ratings Breakdown

Latest NBP, RIGL, FTH, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/20/2026	NBP I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	$2.00 per share	N/A
PHAR Pharming Group	$376.13M	2.16	$0.19 per share	59.09	$3.95 per share	2.90
RIGL Rigel Pharmaceuticals	$276.79M	3.02	$6.62 per share	6.81	$21.57 per share	2.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
NBP I-Mab	-$46.27M	-$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	$2.85M	$0.12	95.50	38.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.76	10.44	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest NBP, RIGL, FTH, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	NBP I-Mab	N/A	-$0.1610	N/A	-$0.1610	N/A	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTH Sensei Biotherapeutics	N/A	19.69	19.69
NBP I-Mab	N/A	7.64	8.09
PHAR Pharming Group	0.34	3.01	2.31
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTH Sensei Biotherapeutics	10.50%
NBP I-Mab	38.38%
PHAR Pharming Group	0.03%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
FTH Sensei Biotherapeutics	7.00%
NBP I-Mab	22.10%
PHAR Pharming Group	2.07%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
NBP I-Mab	380	115.65 million	90.09 million	N/A
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable

NBP, RIGL, FTH, and PHAR Headlines

Recent News About These Companies

Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 24 at 4:31 AM | marketbeat.com

HC Wainwright Issues Optimistic Forecast for RIGL Earnings

August 20, 2026 | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

August 19, 2026 | marketbeat.com

HC Wainwright Analysts Increase Earnings Estimates for RIGL

August 18, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP

August 10, 2026 | marketbeat.com

Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL

August 8, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

August 7, 2026 | marketbeat.com

Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL

August 7, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for RIGL Earnings

August 6, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 6, 2026 | marketbeat.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 5, 2026 | marketbeat.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Rigel Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, RIGL, FTH, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

$34.71 +2.71 (+8.47%)

Closing price 04:00 PM Eastern

Extended Trading

$35.39 +0.68 (+1.96%)

As of 06:50 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

I-Mab NASDAQ:NBP

$1.89 -0.11 (-5.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.03 (+1.75%)

As of 06:19 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Pharming Group NASDAQ:PHAR

$11.46 -0.39 (-3.29%)

Closing price 03:59 PM Eastern

Extended Trading

$11.46 0.00 (0.00%)

As of 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Rigel Pharmaceuticals NASDAQ:RIGL

$45.11 -0.78 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$45.13 +0.02 (+0.04%)

As of 06:53 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBP, RIGL, FTH, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBP, RIGL, FTH, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBP, RIGL, FTH, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, RIGL, FTH, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

I-Mab NASDAQ:NBP

Pharming Group NASDAQ:PHAR

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBP, RIGL, FTH, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBP, RIGL, FTH, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBP, RIGL, FTH, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP, RIGL, FTH, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

I-Mab NASDAQ:NBP

Pharming Group NASDAQ:PHAR

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools